Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Salivary Gland Neoplasms | 1 | 2026 | 64 | 0.920 |
Why?
|
| Mucopolysaccharidosis VII | 2 | 2020 | 4 | 0.750 |
Why?
|
| Enzyme Replacement Therapy | 3 | 2023 | 31 | 0.700 |
Why?
|
| Glycosaminoglycans | 3 | 2020 | 42 | 0.690 |
Why?
|
| Glucuronidase | 2 | 2020 | 32 | 0.650 |
Why?
|
| Mucopolysaccharidosis IV | 1 | 2020 | 3 | 0.640 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2020 | 79 | 0.610 |
Why?
|
| Niemann-Pick Disease, Type C | 3 | 2023 | 7 | 0.520 |
Why?
|
| Congenital Disorders of Glycosylation | 2 | 2023 | 50 | 0.300 |
Why?
|
| Mucopolysaccharidosis I | 2 | 2016 | 25 | 0.240 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 2023 | 13 | 0.210 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 2 | 2020 | 6 | 0.200 |
Why?
|
| Oxysterols | 1 | 2023 | 3 | 0.200 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2023 | 25 | 0.190 |
Why?
|
| Mucopolysaccharidosis III | 1 | 2022 | 14 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 118 | 0.170 |
Why?
|
| Phosphorylcholine | 1 | 2020 | 31 | 0.160 |
Why?
|
| Elasticity | 1 | 2020 | 94 | 0.160 |
Why?
|
| Glycine | 1 | 2020 | 159 | 0.150 |
Why?
|
| Calcium Channels, R-Type | 1 | 2018 | 3 | 0.150 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 154 | 0.150 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 324 | 0.140 |
Why?
|
| Contracture | 1 | 2018 | 26 | 0.140 |
Why?
|
| Dyskinesias | 1 | 2018 | 20 | 0.140 |
Why?
|
| Megalencephaly | 1 | 2018 | 61 | 0.140 |
Why?
|
| Cation Transport Proteins | 1 | 2018 | 101 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 583 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2020 | 207 | 0.130 |
Why?
|
| Spasms, Infantile | 1 | 2018 | 165 | 0.120 |
Why?
|
| Prognosis | 1 | 2026 | 4894 | 0.120 |
Why?
|
| Mucopolysaccharidoses | 1 | 2016 | 7 | 0.120 |
Why?
|
| Adult | 6 | 2026 | 31121 | 0.120 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2016 | 1 | 0.120 |
Why?
|
| Mannosyltransferases | 1 | 2016 | 3 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 522 | 0.120 |
Why?
|
| Myelin Proteins | 1 | 2015 | 78 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2016 | 143 | 0.110 |
Why?
|
| Male | 10 | 2026 | 64524 | 0.110 |
Why?
|
| Corpus Callosum | 1 | 2015 | 109 | 0.110 |
Why?
|
| Myelin Sheath | 1 | 2015 | 128 | 0.110 |
Why?
|
| Female | 10 | 2026 | 70281 | 0.110 |
Why?
|
| Humans | 13 | 2026 | 130380 | 0.100 |
Why?
|
| Disease Management | 1 | 2016 | 559 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 1556 | 0.090 |
Why?
|
| Adolescent | 5 | 2023 | 20749 | 0.090 |
Why?
|
| Child | 6 | 2023 | 26161 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3801 | 0.080 |
Why?
|
| Epilepsy | 1 | 2018 | 872 | 0.080 |
Why?
|
| Aged | 2 | 2026 | 20888 | 0.080 |
Why?
|
| Glycosylation | 2 | 2023 | 126 | 0.080 |
Why?
|
| Bile Acids and Salts | 2 | 2023 | 259 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2020 | 6421 | 0.070 |
Why?
|
| Biomarkers | 4 | 2020 | 3395 | 0.070 |
Why?
|
| Middle Aged | 2 | 2026 | 28376 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 288 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2026 | 17606 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12856 | 0.060 |
Why?
|
| Dogs | 2 | 2016 | 615 | 0.050 |
Why?
|
| alpha-Glucosidases | 1 | 2023 | 33 | 0.050 |
Why?
|
| Infant | 4 | 2023 | 13269 | 0.050 |
Why?
|
| Hydrolases | 1 | 2023 | 61 | 0.050 |
Why?
|
| Triolein | 1 | 2022 | 3 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 6131 | 0.050 |
Why?
|
| Cachexia | 1 | 2022 | 57 | 0.040 |
Why?
|
| Adipose Tissue, Brown | 1 | 2022 | 88 | 0.040 |
Why?
|
| Cats | 1 | 2020 | 113 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 140 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 236 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 877 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2020 | 14984 | 0.030 |
Why?
|
| Animals | 4 | 2022 | 33924 | 0.030 |
Why?
|
| Ireland | 1 | 2016 | 33 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 2016 | 72 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 135 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 91 | 0.030 |
Why?
|
| Iduronidase | 1 | 2015 | 10 | 0.030 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2016 | 39 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 213 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 117 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 185 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2106 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 695 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 9992 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 258 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 599 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1498 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 373 | 0.020 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 622 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2016 | 553 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3816 | 0.020 |
Why?
|
| Brain | 1 | 2023 | 3193 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 3031 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1723 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 3400 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2567 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1291 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 10937 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8492 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4475 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 4001 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 18213 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4664 | 0.010 |
Why?
|